Abstract
Background An outbreak of diphtheria, declared in Yemen in October 2017, is still ongoing. Methods. Probable cases were recorded through an electronic diseases early warning system. Microbiological culture, genomic sequencing, antimicrobial susceptibility and toxin production testing were performed.
Methods Probable cases were recorded through an electronic diseases early warning system. Microbiological culture, genomic sequencing, antimicrobial susceptibility and toxin production testing were performed.
Findings The Yemen diphtheria outbreak developed in three epidemic waves, which affected nearly all governorates (provinces) of Yemen, with 5701 probable cases and 330 deaths (October 2017 - April 2020). The median age of patients was 12 years (range, 0.17-80). Virtually all outbreak isolates (40 of 43 tested ones) produced the diphtheria toxin. We observed low level of antimicrobial resistance to penicillin. We identified six separate Corynebacterium diphtheriae phylogenetic sublineages, three of which are genetically related to isolates from Saudi Arabia and Somalia. The predominant sublineage was resistant to trimethoprim and was associated with unique genomic features, more frequent neck swelling (p=0.002) and a younger age of patients (p=0.06). Its evolutionary rate was estimated at 1.67 × 10−6 substitutions per site year-1, placing its most recent common ancestor in 2015, and indicating silent circulation of C. diphtheriae in Yemen earlier than outbreak declaration.
Interpretation We disclose clinical, epidemiological and microbiological characteristics of one of the largest contemporary diphtheria outbreaks and demonstrate clinically relevant heterogeneity of C. diphtheriae isolates, underlining the need for laboratory capacity and real-time microbiological analyses to inform prevention, treatment and control of diphtheria.
Funding This work was supported by institutional funding from the National Centre of the Public Health Laboratories (Sanaa, Yemen) and Institut Pasteur (Paris, France) and by the French Government Investissement d ‘Avenir Program.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported financially by institutional funding from the NCPHL-Sanaa and Institut Pasteur. The French National Reference Center for Corynebacteria of the diphtheriae complex received support from Institut Pasteur and Public Health France (Sante publique France, Saint Maurice, France). This work was also supported financially by the French Government Investissement dAvenir program Laboratoire dExcellence Integrative Biology of Emerging Infectious Diseases (ANR-10-LABX-62-IBEID). The funders had no role in the study design, collection, analysis, interpretation of the data and manuscript writing. Institut Pasteur and the NCPHL supported the decision to submit the paper for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Data were collected as part of routine case management under an emergency response mandate from the government of Yemen. The scientific committee of the NCPHL, Sanaa authorized the usage of the clinical data included in this study.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The whole genome sequencing data generated in this study were deposited in the European Nucleotide Archive (ENA) database and are accessible through the study PRJEB34206 (https://www.ebi.ac.uk/ena/data/view/PRJEB34206). Raw read data are available under the accessions ERR4332853-96. Contig sequences are available under the accessions CAJDXH01000000-CAJDYY01000000.
